Greenwich Lifesciences Net Worth
Greenwich Lifesciences Net Worth Breakdown | GLSI |
Greenwich Lifesciences Net Worth Analysis
Greenwich Lifesciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Greenwich Lifesciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Greenwich Lifesciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Greenwich Lifesciences' net worth analysis. One common approach is to calculate Greenwich Lifesciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Greenwich Lifesciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Greenwich Lifesciences' net worth. This approach calculates the present value of Greenwich Lifesciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Greenwich Lifesciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Greenwich Lifesciences' net worth. This involves comparing Greenwich Lifesciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Greenwich Lifesciences' net worth relative to its peers.
Enterprise Value |
|
To determine if Greenwich Lifesciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Greenwich Lifesciences' net worth research are outlined below:
| Greenwich Lifesciences had very high historical volatility over the last 90 days | |
| Greenwich Lifesciences has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (8.89 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Greenwich Lifesciences currently holds about 15.64 M in cash with (6.48 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22. | |
| Greenwich Lifesciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 53.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Major Breakthrough Cancer Prevention Trial Goes Europe-Wide as Top Medical Centers Join Forces - StockTitan |
Greenwich Lifesciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Greenwich Lifesciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Greenwich Lifesciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 27th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Greenwich Lifesciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Greenwich Lifesciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Greenwich Lifesciences backward and forwards among themselves. Greenwich Lifesciences' institutional investor refers to the entity that pools money to purchase Greenwich Lifesciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of New York Mellon Corp | 2024-09-30 | 11.2 K | Millennium Management Llc | 2024-09-30 | 10.6 K | Barclays Plc | 2024-09-30 | 8.6 K | Rhumbline Advisers | 2024-09-30 | 6.3 K | New York State Common Retirement Fund | 2024-09-30 | 6 K | Bank Of America Corp | 2024-09-30 | 5.9 K | Citigroup Inc | 2024-09-30 | 4.3 K | Mirae Asset Global Etfs Holdings Ltd. | 2024-09-30 | 3.3 K | Corebridge Financial Inc | 2024-09-30 | 3.2 K | Blackrock Inc | 2024-09-30 | 350.1 K | Vanguard Group Inc | 2024-09-30 | 273.5 K |
Follow Greenwich Lifesciences' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 173.38 M.Market Cap |
|
Project Greenwich Lifesciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.14) | (1.20) | |
| Return On Capital Employed | (1.60) | (1.52) | |
| Return On Assets | (1.14) | (1.20) | |
| Return On Equity | (1.53) | (1.45) |
When accessing Greenwich Lifesciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Greenwich Lifesciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Greenwich Lifesciences' profitability and make more informed investment decisions.
Evaluate Greenwich Lifesciences' management efficiency
Greenwich Lifesciences has return on total asset (ROA) of (0.7245) % which means that it has lost $0.7245 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2367) %, meaning that it created substantial loss on money invested by shareholders. Greenwich Lifesciences' management efficiency ratios could be used to measure how well Greenwich Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.2. The Greenwich Lifesciences' current Return On Capital Employed is estimated to increase to -1.52. As of now, Greenwich Lifesciences' Other Assets are decreasing as compared to previous years.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.52 | 0.47 | |
| Tangible Book Value Per Share | 0.52 | 0.47 | |
| Enterprise Value Over EBITDA | (12.37) | (12.99) | |
| Price Book Value Ratio | 18.16 | 19.06 | |
| Enterprise Value Multiple | (12.37) | (12.99) | |
| Price Fair Value | 18.16 | 19.06 | |
| Enterprise Value | 147.4 M | 240.3 M |
Leadership at Greenwich Lifesciences emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Greenwich Lifesciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Greenwich Lifesciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Greenwich Lifesciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Greenwich Lifesciences Corporate Filings
F4 | 13th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 20th of December 2024 Other Reports | ViewVerify | |
8K | 19th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 14th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Greenwich Lifesciences Earnings per Share Projection vs Actual
Greenwich Lifesciences Corporate Management
| Christine Fischette | VP Development | Profile | |
| Snehal Patel | CFO CEO | Profile | |
| Eric Rothe | Founder Director | Profile | |
| Frank MD | Chief Director | Profile | |
| Jaye Thompson | Vice Affairs | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Greenwich Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Greenwich Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.